Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Oramed Pharmaceuticals Inc. (ORMP) vs Sol-Gel Technologies Ltd. (SLGL)

Oramed Pharmaceuticals Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Oramed Pharmaceuticals Inc. and Sol-Gel Technologies Ltd. are of similar size ($199.3M and $198.9M). Sol-Gel Technologies Ltd. has negative trailing earnings, so its P/E is not meaningful; Oramed Pharmaceuticals Inc. trades at 1.1×. Oramed Pharmaceuticals Inc. grew revenue faster over the last twelve months: 347.8% against −92.5%. Oramed Pharmaceuticals Inc. has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (−3.40% vs −6,630.2%). Across the 17 metrics below, Oramed Pharmaceuticals Inc. leads on 13 and Sol-Gel Technologies Ltd. on 4.

Valuation

Metric ORMP SLGL Biotechnology median
P/E 1.12 n/m 7.88
P/S 48.28 121.82 11.47
P/B 0.61 4.55 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 35.69 95.38 10.73
Earnings yield 89.43% (8.44%) (28.84%)
Free cash flow yield (2.69%) (9.73%) (23.03%)

Profitability

Metric ORMP SLGL Biotechnology median
Gross margin 32.31% 100.00% 65.16%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity 73.90% (40.85%) (57.72%)
Return on assets 65.52% (35.11%) (49.22%)
Return on invested capital (3.40%) (6,630.24%) 0.00%

Growth

Metric ORMP SLGL Biotechnology median
Revenue growth (TTM) 347.77% (92.50%) 5.64%
EPS growth (last fiscal year) 412.50% 42.37% —
Revenue growth, 5-year CAGR (5.85%) 17.19% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ORMP SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.98 10.37 4.73
Net debt to EBITDA 8.41 3.23 0.96

Dividend

Metric ORMP SLGL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ORMP SLGL Biotechnology median
Market cap 199.25m 198.86m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack